Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

SwRI leads $18 million DOD project to develop tularemia “rabbit fever” vaccine for military

By Heather Hall | February 10, 2020

Southwest Research Institute (SwRI), The University of Texas at San Antonio (UTSA) and Lovelace Respiratory Research Institute received an $18 million contract from the U.S. Department of Defense’s Defense Threat Reduction Agency to develop a vaccine against tularemia, a potential biothreat caused by the bacterium Francisella tularensis.

SwRI’s pharmaceutical testing laboratories will formulate UTSA’s modified bacterium for human clinical trials using intradermal injection. The goal is to develop a vaccine formulation that protects humans for up to one year from tularemia, also known as rabbit fever.

SwRI, the principal investigator organization, will assist with improving vaccine stability through chemistry manufacturing controls (CMC) and encapsulation with nanoparticles to extend the immunity with a slow release formulation.

“There is an urgent need to develop a tularemia vaccine that is safe, effective and supported by sufficient data to be approved by the FDA,” said Dr. Joe McDonough, SwRI’s director of Pharmaceuticals and Bioengineering.

The $18 million contract will expand on UTSA researcher Dr. Karl Klose’s development of Fn-igID, a genetically modified strain of Francisella novicida, a relative of the Francisella tularensis bacterium that causes tularemia. Klose and his colleagues previously demonstrated that the Fn-iglD vaccine can protect against airborne Francisella exposure in animal models.

“This is something we discovered in our laboratory, right here in San Antonio, that is now moving one step closer to having a practical outcome of protecting humans against a biothreat,” said Dr. Klose, a professor in UTSA’s Robert J. Kleberg Jr. and Helen C. Kleberg College of Sciences. “It is really exciting, and we couldn’t do it without SwRI and Lovelace, who specialize in formulations, encapsulation and testing. Our close collaboration is enabling all of this to move forward.”

Tularemia is rare in humans. It is generally found in infected animals, particularly rabbits. Aerosolized Francisella is highly infectious and is classified by the U.S. Centers for Disease Control as a Category A biothreat agent. When introduced into the lungs, the bacterium can cause a tularemia infection, which can be potentially fatal. As a result, the bacterium has been developed as an aerosolized bioweapon, posing a threat to national security.

Klose and his research team ultimately decided to develop the vaccine from Francisella novicida, a closely related bacterium that is benign for humans.

Once SwRI and UTSA optimize the vaccine, Lovelace Respiratory Research Institute will conduct advanced testing using more complex scientific models to ensure the efficacy and safety of the vaccine.

The $18 million contract is a significant accomplishment for the Vaccine Development Center of San Antonio (VDCOSA). Founded in 2012 by UTSA, SwRI, Texas Biomedical Research Institute and UT Health San Antonio, the center leverages the strength, expertise and assets of San Antonio’s four leading research institutions to identify and develop promising vaccine candidates to promote public health.

“This program exemplifies the progress that happens when institutions are brought together through partnerships like the Vaccine Development Center of San Antonio,” added Dr. McDonough, a VDCOSA scientific co-director. “By combining SwRI’s medical countermeasure development and formulation development experience with Dr. Klose’s and UTSA’s innovation, we will provide a much-needed solution to a critical problem.”

To learn more, visit SwRI’s pharmaceutical testing laboratories and VDCOSA.

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE